Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Eisai Co., Ltd    4523   JP3160400002

EISAI CO., LTD (4523)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25 Mg in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/13/2017 | 03:31pm CET

TOKYO, Oct. 13 -- Eisai issued the following news release:

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), Toyama Chemical Co., Ltd. of the Fujifilm Group (Headquarters: Tokyo, President: Junji Okada, "Toyama Chemical") and Taisho Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Chief Executive Officer: Shigeru Uehara, "Taisho Pharmaceutical") announced today that Eisai will acquire the marketing authorization and take over the marketing activities for anti-rheumatic agent KOLBET (R) Tablets 25mg (generic name: iguratimod), based on an agreement between the companies. Currently, Toyama Chemical holds the marketing authorization and manufactures the agent, while Taisho Pharmaceutical hold the rights to market the agent, which it exercises through Taisho Toyama Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Kenichi Fujita, "TaishoToyama").

Transfer of the marketing authorization for the agent from Toyama Chemical to Eisai and transfer of the marketing activites from Taisho Pharmaceutical and TaishoToyama to Eisai are scheduled to take place on January 1, 2018. Toyama Chemical will continue to manufacture the agent.

Iguratimod is an active ingredient developed by Toyama Chemical. It is a Disease Modifying Anti- Rheumatic Drug (DMARD) which exhibits an anti-rhematic effect mainly by suppressing production of immunoglobulin and inflammatory cytokines. Iguratimod demonstrated efficacy as monotherapy in a domestic clinical study for rheumatoid arthritis patients, and in a combination study with methotrexate (MTX), the standard of care, it was the first orally-administered anti-rheumatic drug in Japan to demonstrate efficacy as an add-on therapy to MTX in patients who responded inadequately to MTX monotherapy.

Iguratimod is sold by Eisai and Taisho Toyama under the brand names Careram (R) Tablets 25 mg and KOLBET (R) Tablets 25 mg, respectively, with both companies working to market the product and provide information on its proper use. Based on this transfer of the marketing authorization and marketing activities, Eisai will be the sole distributor of iguratimod in Japan.

Eisai, Toyama Chemical, Taisho Pharmaceutical and TaishoToyama will cooperate to ensure the smooth transfer of the marketing authorization and marketing activities for KOLBET tablets.

Targeted News Service, source News Service

Valeurs citées dans l'article
ChangeLast1st jan.
FUJIFILM HOLDINGS CORP -0.80% 4323 End-of-day quote.-8.14%
TAISHO PHARMACEUTICAL INDONESIA TBK PT --End-of-day quote.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EISAI CO., LTD
02/21EISAI : H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Splic..
AQ
02/21EISAI : Certified in 2018 as outstanding health and productivity management orga..
AQ
02/21EISAI : H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Splic..
AQ
02/21EISAI : Certified in 2018 as Outstanding Health and Productivity Management Orga..
AQ
02/20EISAI : U.k. nice recommends anticancer agent lenvima as treatment for thyroid c..
AQ
02/20BIOARCTIC : Full Year Report January - December 2017
AQ
02/19EISAI : Positive Phase 3 Trial Results of Investigational Anticancer Agent Lenva..
AQ
02/16EISAI : U.K. Nice Recommends Anticancer Agent Lenvima as Treatment for Thyroid C..
AQ
02/15EISAI : U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid C..
AQ
02/13EISAI : Eisai contributes to taiwan earthquake relief efforts
AQ
More news
News from SeekingAlpha
02/15FDA issues draft industry guidance for early-stage Alzheimer's disease 
02/05Eisai's (ESALF) Management on Q3 2017 Results - Earnings Call Transcript 
02/02Eisai Co., Ltd. 2017 Q3 - Results - Earnings Call Slides 
02/02Eisai reports 9M results 
01/21WEEK IN REVIEW : Sinocare Eyes $4 Billion Deal For J&J Diabetes Device Business 
Financials ( JPY)
Sales 2018 573 B
EBIT 2018 -
Net income 2018 38 210 M
Debt 2018 15 647 M
Yield 2018 2,67%
P/E ratio 2018 41,59
P/E ratio 2019 45,49
EV / Sales 2018 2,93x
EV / Sales 2019 2,92x
Capitalization 1 664 B
Chart EISAI CO., LTD
Duration : Period :
Eisai Co., Ltd Technical Analysis Chart | 4523 | JP3160400002 | 4-Traders
Technical analysis trends EISAI CO., LTD
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 6 620  JPY
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer & Chief IR Officer
Hideki Hayashi Chief Information Officer
Nobuo Deguchi Director
Noboru Naoe Director
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD-14.27%15 473
JOHNSON & JOHNSON-6.33%349 006
NOVARTIS-2.67%224 221
PFIZER-0.58%213 155
ROCHE HOLDING LTD.-9.33%206 183
MERCK AND COMPANY-2.29%148 618